● neutral
Impact
PhasePreclinical
Time to marketAt least 5-7 years away from potential approval, assuming successful IND filing in 2027, completion of Phase 1-3 trials, and regulatory review. The program has not yet entered human testing.
BBP-717 Updated Oct 29
What to watch
BBP-717 is too early-stage to drive near-term stock movement. The next catalyst to watch is the planned IND filing in 2027, but no specific date has been set. Investors should focus on BridgeBio's nearer-term catalysts: the BBP-418 PDUFA decision on November 27, 2026, and the commercial ramp of Attruby (acoramidis) for ATTR-CM.
Bull case
- BBP-717 targets a large unmet need: there are no approved therapies that actively clear existing TTR amyloid deposits from the heart, only stabilizers that prevent new deposits. If successful, BBP-717 could enable disease reversal in ATTR-CM patients.
- BridgeBio has deep expertise in ATTR-CM through its approved drug Attruby (acoramidis), giving it a strong scientific and commercial foundation for a next-generation depleter antibody.
- The ATTR-CM market is large and growing: Attruby generated significant Q3 2026 revenue, and a depleter could address patients who already have significant amyloid burden.
Bear case
- BBP-717 is at the preclinical stage and has not yet entered human trials; most preclinical drug candidates fail to reach the market.
- Alexion/AstraZeneca's ALXN2220 (cliramitug/NI006), a similar amyloid-depleter antibody, is already in Phase 3 testing (DepleTTR-CM trial), giving it a multi-year head start over BBP-717.
- BBP-717 is a small program within BridgeBio's broad pipeline; the company has many nearer-term priorities including the BBP-418 PDUFA, Attruby commercial expansion, and multiple other clinical programs, so BBP-717 is unlikely to be a near-term value driver.